Artificial intelligence in pharma, health care is at the crossroads of hype and reality
But along with enthusiasm in areas as diverse as phenotypic screening, drug repositioning, and CT analysis, we are also finding a growing sk
CAR-T: What’s next? Part 2
In my previous blog post, I suggested that the market size for gene-modified T-cell therapies would be roughly $9 Bn in 10 years, with a...
CAR-T: What’s next? Part 1
Over the last two months, several news events have brought CAR-T cells to widespread public attention, the most prominent of which is the...
Pharmacy Benefit Managers (PBMs): Bending the cost curve in the wrong direction
In the NY Times article, “Take the Generic, Patients Are Told. Until They Are Not.”, Pharmacy Benefit Managers (PBMs) were called out for...
